Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04807881 | Phase Ib Clinical Study of Keynatinib | recruiting | Phase 1 | 75 | Medolution Ltd.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 |
| clinicaltrials |
| NCT06096272 | Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy | recruiting | N/A | 30 | Children's Hospital Los AngelesOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782789 | An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program(TALOs) | recruiting | — | 96 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783790 | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783816 | A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors | recruiting | N/A | 45 | Shanxi Bethune HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06785077 | Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors | recruiting | N/A | 157 | European Institute of OncologyOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06781437 | Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)(RETRO-LYMPH) | recruiting | — | 5,500 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06781515 | Assessment of Disease Burden in Hairy Cell Leukemia(BRAF) | recruiting | N/A | 45 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06225310 | A Trial of Selinexor, Ruxolitinib and Methylprednisolone(KPT-IST-391) | recruiting | Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774326 | Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines(AntraCardioTox) | recruiting | — | 160 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774677 | Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 30 | John ListerOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06179524 | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | recruiting | Phase 2 | 100 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05528939 | Feasibility/Acceptability of Attentional-Control Training in Survivors(FAACTS) | recruiting | N/A | 50 | Children's National Research InstituteOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06767254 | A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence | recruiting | — | 200 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06764524 | Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 7 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06761274 | Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma(MEPI-AGE) | recruiting | N/A | 200 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma(UHKT-CAR19-01) | recruiting | Phase 1 | 10 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06758713 | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies | recruiting | Phase 1 | 60 | The Third Affiliated Hospital of Southern Medical UniversityOTHER_GOV | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06734871 | A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma(CT1190B) | recruiting | Phase 1 | 24 | Aibin Liang，MD，Ph.D.OTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06755619 | CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)(CAPCI) | recruiting | — | 60 | Nordic Lymphoma GroupNETWORK | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06755775 | PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma | recruiting | — | 150 | Ruijin HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis | recruiting | Phase 2 / Phase 3 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06752785 | CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. | recruiting | Phase 1 | 10 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05958719 | Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma | recruiting | Phase 2 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06701357 | CR-CHOP+X in Previously Untreated DEL | recruiting | Phase 2 | 49 | Ruijin HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05501379 | Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker(OncoPhys) | recruiting | — | 60 | University Medicine GreifswaldOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05690581 | Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies | recruiting | Phase 1 | 146 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05807789 | Molecular-genetic Characterization in Patients Undergoing CAR-T Cell Infusion(CAR_22) | recruiting | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06363994 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | recruiting | Phase 3 | 476 | InnoCare Pharma Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06690593 | Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy | recruiting | — | 2,990 | Zhujiang HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06740916 | Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance | recruiting | Phase 3 | 240 | Siriraj HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06741722 | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | recruiting | Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05967416 | Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 | 24 | SIRPant Immunotherapeutics, Inc.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06082284 | A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method. | recruiting | — | 10,000 | Zhujiang HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT06026488 | Real-World Study of DLBCL With Different Genetic Subtypes | recruiting | — | 10,000 | Ruijin HospitalOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06332430 | Intratumoral CAN2109 in Subjects With Solid Tumors | recruiting | Phase 1 | 27 | Canwell Biotech LimitedINDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06561854 | Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone(FREEDOM) | recruiting | Phase 3 | 318 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06739265 | Golidocitinib Plus CHOP in Newly Diagnosed PTCL | recruiting | Phase 1 / Phase 2 | 68 | Peking Union Medical College HospitalOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04466059 | Better Leukemia Diagnostics Through AI (BELUGA)(BELUGA) | recruiting | — | 25,000 | Munich Leukemia LaboratoryINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05046444 | Solving Riddles Through Sequencing(SIRIUS) | recruiting | — | 100 | Munich Leukemia LaboratoryINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05839717 | Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)(CLOJAK) | recruiting | — | 120 | University Hospital, BordeauxOTHER | 1 | Dec 17, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 22, 2025source: clinicaltrials